Pacira BioSciences, Inc. PCRX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total net product sales by Product | ||||||
| Bupivacaine liposome injectable suspension | $1.16M-55.5% | $1.11M— | $2.69M+63.8% | $508K-83.9% | $2.6M+3.1% | |
| EXPAREL | $143.27M+4.9% | $155.78M+5.5% | $139.9M+6.0% | $142.92M+4.4% | $136.53M+3.1% | |
| iovera° | $6.18M+20.6% | $7M+8.5% | $6.47M+14.3% | $5.59M-1.5% | $5.12M+1.8% | |
| ZILRETTA | $26.77M+14.7% | $32.98M-0.4% | $28.98M+2.0% | $31.33M+2.0% | $23.34M-9.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Pacira BioSciences, Inc. break its business down?
- Pacira BioSciences, Inc. (PCRX) reports total net product sales by product across 4 parts — Bupivacaine liposome injectable suspension, EXPAREL, iovera° and ZILRETTA. Each is extracted from the segment footnotes and tracked over time.
- Where does Pacira BioSciences, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Pacira BioSciences, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
